3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Lymphoma, Large B-Cell, Diffuse
43
Breast Neoplasms
30
Lymphoma
28
Sarcoma
26
Hodgkin Disease
24
Triple Negative Breast Neoplasms
20
Burkitt Lymphoma
19
Precursor Cell Lymphoblastic Leukemia-Lymphoma
18
Lymphoma, Follicular
16
Neoplasms
15
Ovarian Neoplasms
14
Lymphoma, Non-Hodgkin
13
Lymphoma, B-Cell
13
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
9
Lymphoma, T-Cell, Peripheral
9
Endometrial Neoplasms
9
Neuroblastoma
7
Neoplasm Metastasis
7
Lymphoma, Mantle-Cell
7
Liposarcoma
7
Leukemia
7
Fallopian Tube Neoplasms
7
Recurrence
6
Multiple Myeloma
6
Leiomyosarcoma
6
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
5
Lymphoma, B-Cell, Marginal Zone
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Inflammatory Breast Neoplasms
5
Histiocytoma, Malignant Fibrous
5
Interventions
tazemetostat
1
relatlimab
1
durvalumab
1
brigimadlin
1
bintrafusp alfa protein, human
1
Nivolumab
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Tertiary Lymphoid Structures
×
Doxorubicin
×
1 year
×
Clear all
NCT04874311
2025-08-13
TRUST
Institut Bergonié
Phase 2
Recruiting
80 enrolled